Home/Nuvalent/Darlene Noci
DN

Darlene Noci

Chief Development Officer

Nuvalent

Nuvalent Pipeline

DrugIndicationPhase
Zidesamtinib (NVL-520)TKI pre-treated advanced ROS1+ NSCLCPhase 2
Neladalkib (NVL-655)TKI pre-treated advanced ALK+ NSCLCPhase 2
NVL-330Advanced HER2-altered NSCLCPhase 1